San Jose, Calif. and Bengaluru, India: Tredence, a global AI and data science solutions company, has announced the acquisition of KMK Consulting, a specialized analytics and consulting firm with deep expertise in the Life Sciences and Biopharma industry.
The acquisition of KMK Consulting marks a significant strategic move for Tredence as it seeks to strengthen its presence in the Healthcare & Life Sciences (HLS) sector.
Headquartered in Morris Plains, New Jersey, KMK Consulting works with eight of the world’s top ten pharmaceutical companies and brings more than two decades of expertise in pharmaceuticals and life sciences.
The company has established strong capabilities across commercial analytics, real-world evidence (RWE), and market research.
The acquisition comes at a time when the global market for AI in Life Sciences is projected to reach $69.3 billion by 2031.
Tredence believes Healthcare & Life Sciences will emerge as its next major growth frontier and expects the HLS business to contribute approximately 25% of the company’s overall revenue over the medium term.
By combining KMK Consulting’s extensive Life Sciences domain expertise with Tredence’s advanced Agentic AI capabilities, the combined entity aims to deliver differentiated offerings for Life Sciences customers.
The integration is expected to help organizations accelerate their Agentic AI adoption, particularly in process-intensive areas that have traditionally been slow to transform and where large-scale data utilization is creating new opportunities for value generation.
The acquisition positions Tredence as an AI partner across the complete Molecule-to-Market journey by integrating KMK Consulting’s domain knowledge with Tredence’s strengths in applied AI, data engineering, and decision intelligence.
The combined capabilities are expected to compress timelines from research and development to commercial launch, enabling faster value delivery across the pharmaceutical value chain.
Also Read: Shree Refrigerations Expands Manufacturing Capacity with New Defence HVAC&R Plant in Maharashtra
The deal also enhances Tredence’s standing within the Veeva ecosystem. Veeva is among the leading cloud-based CRM and data platforms built specifically for the Life Sciences industry and is used by an estimated 60–70% of pharmaceutical companies globally to manage commercial operations, medical engagement, and incentive compensation.
As pharmaceutical companies continue to increase investments in AI, the acquisition places Tredence at the center of ongoing digital transformation within the sector.
With advances in agentic AI reshaping traditional service models, the combination of deep industry expertise and advanced AI capabilities is expected to serve as a key differentiator.
Shub Bhowmick, Co-Founder & CEO, Tredence, said: “While Tredence has consistently operated at the leading edge of AI and Data Science, our true differentiator has always been deep domain expertise.
The acquisition of KMK reinforces this philosophy, bringing unparalleled strength in Pharmaceuticals and Life sciences. Together, we are accelerating our ambition to become a premier provider of AI solutions for this critical sector”.
Michael Karbachinskiy, Founder & CEO, KMK Consulting, said: “At KMK, our foundation has always been deep, long-standing expertise in Life sciences—understanding not just the science, but how it translates into real-world decisions and outcomes.
With Tredence’s strength in AI and Data Science, we now have the opportunity to amplify that expertise and deliver even greater impact to our clients.”
Prashant Sareen, Head of Healthcare & Life Sciences at Tredence, added: “We have built a strong HLS foundation, helping global pharma companies accelerate R&D, modernize supply chains, and scale AI in production.
KMK Consulting’s domain depth is genuinely differentiated and, when combined with Tredence’s, it enables us to deliver value in fundamentally new ways. This further advances everything we have been building in HLS”.
